Table 1.
Baseline characteristics of included studies.
| References | Country | Study design | Patients of group | Regimens | Total patients |
|---|---|---|---|---|---|
| Olivera et al. 13 | Spain | Retrospective Study | 118 | Edoxaban | 232 |
| 114 | Enoxaparin | ||||
| Kumar et al. 14 | India | RCT | 115 | Rivaroxaban | 228 |
| 113 | Enoxaparin | ||||
| ACTION15 | Brazil | RCT | 310 | Rivaroxaban | 614 |
| 304 | Enoxaparin or UFH | ||||
| Appiah16 | USA | Retrospective Study | 75 | Apixaban | 162 |
| 87 | Enoxaparin | ||||
| Mohammed et al. 17 | Egypt | RCT | 58 | Rivaroxaban | 124 |
| 66 | Enoxaparin | ||||
| FREEDOM COVID19 | USA | RCT | 1121 | Apixaban | 2257 |
| 1136 | Enoxaparin | ||||
| COVID-PREVENT18 | Germany | RCT | 55 | Rivaroxaban | 111 |
| 56 | Enoxaparin | ||||
| MICHELLE20 | Brazil | RCT | 160 | Rivaroxaban | 320 |
| 160 | Enoxaparin |
RCT, randomized controlled trial; UFH, unfractionated heparin.